The content on this site is intended for healthcare professionals only
Dr G Thomas Budd presents data on a phase III randomised clinical trial that found low-dose weekly administration of paclitaxel and standard dose, every two weeks administration, resulted in equal progression-free survival for women with higher-risk early-stage breast cancer who have undergone surgery.
However, researchers found that certain side effects were more common with the every two weeks regimen, suggesting the weekly schedule may be preferable.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Breast cancer survivorship
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Latest in EGFR mutated NSCLC
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
